Servier will manufacture an oral anticoagulant in Russia


Servier JSC and Daiichi Sankyo Europe have signed a strategic license agreement under which Servier JSC received the rights to manufacture/package edoxaban, an oral anticoagulant, at its pharmaceutical plant in Moscow, Russia, and market it in Albania, Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Montenegro, Russia, Serbia, Tajikistan, Turkmenistan, Ukraine, and Uzbekistan following its state registration by the authorities in charge of circulation of medicinal products.

Under the name of LIXIANA®, edoxaban is registered and used for patient treatment in Switzerland, Japan, South Korea, Taiwan, Thailand, Hong Kong, UK, Germany, Ireland, Netherlands, Italy, Spain, Austria, Portugal and other countries of the European Union.

Jérôme Gavet, the Managing Director of Servier Russia & Eurasian Economic Union said, “In our daily activities, we strive for continuous improvement of methods used in the treatment of chronic non-infectious diseases. I am convinced that edoxaban will effectively complement the company’s existing portfolio of medicinal products for cardiovascular diseases (CVD) and will make a significant contribution to improving the outcomes of treatment for patients suffering from CVD not only to improve their quality of life but also to extend their life expectancy.”